{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:27Z","timestamp":1793394087767,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.transci.2026.104437","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:30:31Z","timestamp":1776871831000},"page":"104437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spleen tyrosine kinase inhibitors for immune thrombocytopenia: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"65","author":[{"given":"Nivia Lavinia Chagas","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Oliveira Souza","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Brenon de","family":"Oliveira Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton Vieira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2026.104437_bib1","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.transci.2026.104437_bib2","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.transci.2026.104437_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ajh.25092","article-title":"Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices","volume":"93","author":"Cuker","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.transci.2026.104437_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia \u2013 current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"7","key":"10.1016\/j.transci.2026.104437_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.186.7.1027","article-title":"A critical role for Syk in signal transduction and phagocytosis mediated by Fc\u03b3 receptors on macrophages","volume":"186","author":"Crowley","year":"1997","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.transci.2026.104437_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2026.104437_bib7","unstructured":"Center for Drug Evaluation. FDA approves fostamatinib tablets for ITP. FDA [Internet]. 2019 [cited 2024 Feb 4]. Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fostamatinib-tablets-itp\u3009."},{"issue":"22","key":"10.1016\/j.transci.2026.104437_bib8","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.transci.2026.104437_bib9","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2022-169652","article-title":"Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia","volume":"140","author":"Kuter","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transci.2026.104437_bib10","unstructured":"ClinicalTrials.gov. Studies found for: SYK inhibitor AND ITP [Internet]. U.S. National Library of Medicine; 2025 Jul [cited 2025 Jul 4]. Available from: \u3008https:\/\/clinicaltrials.gov\/search?term=SYK+inhibitor+ITP&recrs=a&cond=Immune+Thrombocytopenia\u3009."},{"key":"10.1016\/j.transci.2026.104437_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/jha2.939","article-title":"Fostamatinib for immune thrombocytopenic purpura in adult patients: a systematic review and meta-analysis","volume":"5","author":"Kou","year":"2024","journal-title":"eJHaem"},{"issue":"10","key":"10.1016\/j.transci.2026.104437_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.transci.2026.104437_bib13","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.transci.2026.104437_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo\u2010controlled, double\u2010blind, parallel\u2010group study","volume":"200","author":"Kuwana","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.transci.2026.104437_bib15","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"11","author":"Hu","year":"2024","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.transci.2026.104437_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.transci.2026.104437_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/jox13010005","article-title":"Safety and efficacy of tyrosine kinase inhibitors in immune thrombocytopenic purpura: a systematic review of clinical trials","volume":"13","author":"Ali","year":"2023","journal-title":"J Xenobiot"},{"issue":"6","key":"10.1016\/j.transci.2026.104437_bib18","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","article-title":"Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis","volume":"38","author":"Wojciechowski","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.transci.2026.104437_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","article-title":"Therapeutic options for adult patients with previously treated immune thrombocytopenia \u2013 a systematic review and network meta-analysis","volume":"24","author":"Yang","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.transci.2026.104437_bib20","first-page":"1","article-title":"Fostamatinib or thrombopoietin for the treatment of chronic immune thrombocytopenia in adult patients: a real-world assessment of safety, effectiveness and cost","volume":"146","author":"Dranitsaris","year":"2023","journal-title":"Acta Haematol"},{"key":"10.1016\/j.transci.2026.104437_bib21","unstructured":"A study on the safety and efficacy of TQB3473 tablets in the treatment of persistent or chronic primary immune thrombocytopenia (ITP) [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Aug 2]. Report No.: NCT07083739. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT07083739\u3009."},{"key":"10.1016\/j.transci.2026.104437_bib22","unstructured":"The safety, tolerability, pharmacokinetics, and preliminary efficacy of HMPL-523 in adult subjects with immune thrombocytopenia (ITP) [Internet]. ClinicalTrials.gov; 2024 [cited 2025 Aug 2]. Report No.: NCT06291415. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06291415\u3009."},{"key":"10.1016\/j.transci.2026.104437_bib23","unstructured":"A study of TQB3473 tablets compared to placebo in the treatment of adult primary immune thrombocytopenia [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Aug 2]. Report No.: NCT06900920. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06900920\u3009."}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:35:14Z","timestamp":1781105714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050226000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1473050226000698"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2026.104437","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spleen tyrosine kinase inhibitors for immune thrombocytopenia: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2026.104437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104437"}}